Neonatal hyperbilirubinemia and organic anion transporting polypeptide-2 gene mutations. 2011

Gökhan Büyükkale, and Gülcan Turker, and Murat Kasap, and Gürler Akpınar, and Engin Arısoy, and Ayla Günlemez, and Ayse Gökalp
Department of Neonatology, Kocaeli University, Turkey.

The aim of this study was to investigate the genotypic distribution of organic anion transporting polypeptide 2 (OATP-2) gene mutations and the relationship with hyperbilirubinemia of unknown etiology. Polymerase chain reaction, restriction fragment length polymorphism, and agarose gel electrophoresis techniques were used for detection of OATP-2 gene mutations in 155 newborn infants: 37 with unexplained hyperbilirubinemia, 65 with explained hyperbilirubinemia, and 53 without hyperbilirubinemia. In the OATP-2 gene, we identified A→G transitions at nucleotide positions 388 and 411 and observed six polymorphic forms. The 388/411-411 mutation was the most common form (43%) in subjects with hyperbilirubinemia of unknown etiology. Male sex [odds ratio (OR): 3.08] and two polymorphic forms of the OATP-2 gene [the 388/411-411 A→G mutation (OR: 3.6) and the 388-411 mutation (OR: 2.4)] increased the risk of neonatal hyperbilirubinemia. In male infants with the 388 A→G mutation of the OATP-2 gene, the levels of unconjugated bilirubin in plasma were significantly increased compared with those observed in females. The polymorphic forms of 388 nucleotide of the OATP-2 gene were identified as risk factors for hyperbilirubinemia of unknown etiology.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D005260 Female Females
D005955 Glucosephosphate Dehydrogenase Deficiency A disease-producing enzyme deficiency subject to many variants, some of which cause a deficiency of GLUCOSE-6-PHOSPHATE DEHYDROGENASE activity in erythrocytes, leading to hemolytic anemia. Deficiency of Glucose-6-Phosphate Dehydrogenase,Deficiency, GPD,Deficiency, Glucosephosphate Dehydrogenase,G6PD Deficiency,GPD Deficiency,Glucose 6 Phosphate Dehydrogenase Deficiency,Glucose-6-Phosphate Dehydrogenase Deficiency,Glucosephosphate Dehydrogenase Deficiencies,Hemolytic Anemia Due to G6PD Deficiency,Deficiencies, G6PD,Deficiencies, GPD,Deficiencies, Glucose-6-Phosphate Dehydrogenase,Deficiencies, Glucosephosphate Dehydrogenase,Deficiency of Glucose 6 Phosphate Dehydrogenase,Deficiency, G6PD,Deficiency, Glucose-6-Phosphate Dehydrogenase,Dehydrogenase Deficiencies, Glucose-6-Phosphate,Dehydrogenase Deficiencies, Glucosephosphate,Dehydrogenase Deficiency, Glucose-6-Phosphate,Dehydrogenase Deficiency, Glucosephosphate,G6PD Deficiencies,GPD Deficiencies,Glucose-6-Phosphate Dehydrogenase Deficiencies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012737 Sex Factors Maleness or femaleness as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or effect of a circumstance. It is used with human or animal concepts but should be differentiated from SEX CHARACTERISTICS, anatomical or physiological manifestations of sex, and from SEX DISTRIBUTION, the number of males and females in given circumstances. Factor, Sex,Factors, Sex,Sex Factor
D014421 Turkey Country in Southeastern Europe and Southwestern Asia bordering the Black Sea, between Bulgaria and Georgia, and bordering the Aegean Sea and the Mediterranean Sea, between Greece and Syria. The capital is Ankara. Turkiye
D016015 Logistic Models Statistical models which describe the relationship between a qualitative dependent variable (that is, one which can take only certain discrete values, such as the presence or absence of a disease) and an independent variable. A common application is in epidemiology for estimating an individual's risk (probability of a disease) as a function of a given risk factor. Logistic Regression,Logit Models,Models, Logistic,Logistic Model,Logistic Regressions,Logit Model,Model, Logistic,Model, Logit,Models, Logit,Regression, Logistic,Regressions, Logistic
D016017 Odds Ratio The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases. Cross-Product Ratio,Risk Ratio,Relative Odds,Cross Product Ratio,Cross-Product Ratios,Odds Ratios,Odds, Relative,Ratio, Cross-Product,Ratio, Risk,Ratios, Cross-Product,Ratios, Risk,Risk Ratios

Related Publications

Gökhan Büyükkale, and Gülcan Turker, and Murat Kasap, and Gürler Akpınar, and Engin Arısoy, and Ayla Günlemez, and Ayse Gökalp
October 1997, The Journal of biological chemistry,
Gökhan Büyükkale, and Gülcan Turker, and Murat Kasap, and Gürler Akpınar, and Engin Arısoy, and Ayla Günlemez, and Ayse Gökalp
December 2009, The Malaysian journal of pathology,
Gökhan Büyükkale, and Gülcan Turker, and Murat Kasap, and Gürler Akpınar, and Engin Arısoy, and Ayla Günlemez, and Ayse Gökalp
July 2009, The Journal of steroid biochemistry and molecular biology,
Gökhan Büyükkale, and Gülcan Turker, and Murat Kasap, and Gürler Akpınar, and Engin Arısoy, and Ayla Günlemez, and Ayse Gökalp
August 2002, Biochimica et biophysica acta,
Gökhan Büyükkale, and Gülcan Turker, and Murat Kasap, and Gürler Akpınar, and Engin Arısoy, and Ayla Günlemez, and Ayse Gökalp
November 2004, Chemico-biological interactions,
Gökhan Büyükkale, and Gülcan Turker, and Murat Kasap, and Gürler Akpınar, and Engin Arısoy, and Ayla Günlemez, and Ayse Gökalp
March 2009, Pharmacogenomics,
Gökhan Büyükkale, and Gülcan Turker, and Murat Kasap, and Gürler Akpınar, and Engin Arısoy, and Ayla Günlemez, and Ayse Gökalp
February 1999, FEBS letters,
Gökhan Büyükkale, and Gülcan Turker, and Murat Kasap, and Gürler Akpınar, and Engin Arısoy, and Ayla Günlemez, and Ayse Gökalp
February 2017, Molecular pharmaceutics,
Gökhan Büyükkale, and Gülcan Turker, and Murat Kasap, and Gürler Akpınar, and Engin Arısoy, and Ayla Günlemez, and Ayse Gökalp
October 2007, Acta pharmacologica Sinica,
Gökhan Büyükkale, and Gülcan Turker, and Murat Kasap, and Gürler Akpınar, and Engin Arısoy, and Ayla Günlemez, and Ayse Gökalp
December 2013, American journal of physiology. Cell physiology,
Copied contents to your clipboard!